Localisation of mesenchymal tumours by somatostatin receptor imaging

Suzanne M. De Jan Beur, Elizabeth A. Streeten, A. Cahid Civelek, Edward F. McCarthy, Liliana Uribe, Stephen J. Marx, Olufunmilayo Onobrakpeya, Lawrence G. Raisz, Nelson B. Watts, Michael Sharon, Michael A. Levine

Research output: Contribution to journalArticlepeer-review

Abstract

Oncogenic osteomalacia, an acquired hypophosphataemic syndrome associated with mesenchymal tumours, is characterised by hypophosphataemia secondary to inappropriate phosphaturia, reduced concentrations of serum calcitriol, and defective bone mineralisation. Removal of these tumours results in complete reversal of these biochemical defects. However, because these tumours are small, slow-growing, and frequently situated in unusual anatomical sites, conventional imaging techniques often fail to detect them. Since mesenchymal tumours express somatostatin receptors, we postulated that somatostatin analogues would be able to detect these tumours. We did Indium-111 labeled pentetreotide imaging in seven patients with oncogenic osteomalacia. In five patients, we identified a mesenchymal tumour, and clinical improvement occurred after tumour resection. Our findings suggest that 111In-pentetreotide imaging effectively detects occult mesenchymal tumours and facilitates surgical treatment of oncogenic osteomalacia.

Original languageEnglish (US)
Pages (from-to)761-763
Number of pages3
JournalLancet
Volume359
Issue number9308
DOIs
StatePublished - Mar 2 2002

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Localisation of mesenchymal tumours by somatostatin receptor imaging'. Together they form a unique fingerprint.

Cite this